All clinical trials on the European Union Clinical Trials Register (EUCTR) must report their results in the registry within a year of completion. This site tracks who's doing this and who isn't. Learn more »
These trials completed more than 12 months ago and should have reported results.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
| Status | Trial ID | Title | Completion date | Category |
|---|---|---|---|---|
| Completed, but no date, and reported results | 2004-000808-40 | Randomized, open label, multi-center, phase III study on pharmacokinetics, pharmacodynamics, efficacy and safety of Goserelin 1M Implant HEXAL in patients with advanced prostatic cancer in comparison ... | bad-data | |
| Completed, but no date, and reported results | 2004-002766-37 | Open-label, multi-center, non-controlled follow-up study over 3-months on the safety of Formoterol Easyhaler® in approximately 35 asthmatic pediatric patients initially treated in study 2003-51-DPI-2 | bad-data | |
| Reported results | 2004-003956-20 | Multi-center, double-blind, double-dummy, controlled, randomized phase III study on the tolerability and efficacy of Diclofenac Sodium 150 mg o.d. in comparison to Voltaren® 50 t.i.d. and Voltaren® Di... | 2005-09-26 | due-trials |
| Reported results | 2005-001279-36 | RANDOMIZED, OPEN LABEL, MULTICENTER, PHASE II STUDY ON PHARMACOKINETICS, PHARMACODYNAMICS, EFFICACY AND SAFETY OF GOSERELIN 3M IMPLANT HEXAL IN PATIENTS WITH ADVANCED PROSTATIC CANCER IN COMPARISON TO... | 2006-09-05 | due-trials |
| Reported results | 2005-002873-62 | RANDOMIZED, OPEN LABEL, MULTICENTER, PHASE II STUDY ON PHARMACOKINETICS, PHARMACODYNAMICS, EFFICACY AND SAFETY OF BUSERELIN 3M IMPLANT HEXAL IN PATIENTS WITH ADVANCED PROSTATIC CANCER IN COMPARISON TO... | 2006-10-17 | due-trials |
| Reported results | 2006-002506-58 | Long-term phase IV multicentre study on the safety and efficacy of Omnitrope® (rhGH) in short children born Small for Gestational Age (SGA) | 2022-03-25 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2007-000134-39 | Double-blind, double-dummy, multi-center, randomized parallel group trial to demonstrate therapeutic equivalence of Salmeterol/Fluticasone MDI HEXAL (25 µg/125 µg per actuation) versus SeretideTM 125 ... | 2008-01-08 | bad-data |
| Reported results | 2007-000135-26 | Double-blind, double-dummy, multi-center, randomized parallel group trial to demonstrate therapeutic equivalence of Salmeterol/Fluticasone MDI HEXAL (25 µg/50 µg per actuation) versus SeretideTM 50 (2... | 2008-06-05 | due-trials |
| Reported results | 2007-001364-72 | Long-term safety follow-up after growth hormone treatment (rhGH) of short children born Small for Gestational Age (SGA) | 2018-07-19 | due-trials |
| Reported results | 2007-001906-26 | Randomized, controlled, double-blind multicenter safety study to evaluate the safety and immunogenicity of subcutaneous EPO HEXAL vs. ERYPO® in the treatment of anemia associated with chronic renal in... | 2010-02-19 | due-trials |
| Reported results | 2007-005235-29 | Efficacy and safety of Salmeterol/Fluticasone MDI HEXAL versus SeretideTM EvohalerTM in adolescent and adult patients with moderate-to-severe persistent asthma: A 12-week, multicenter, randomized, dou... | 2009-04-27 | due-trials |
| Reported results | 2007-005620-32 | Efficacy and safety of Salmeterol/Fluticasone DPI HEXAL versus Seretide™ Accuhaler™ in adolescent and adult patients with moderate-to-severe persistent asthma: A 12-week, multicenter, randomized, doub... | 2010-04-02 | due-trials |
| Reported results | 2007-005630-36 | Double-blind, double-dummy, multi-center, randomized parallel group study to demonstrate therapeutic equivalence of Salmeterol/Fluticasone DPI HEXAL versus Seretide™ 100 Accuhaler™ over a period of 12... | 2010-02-22 | due-trials |
| Reported results | 2007-005728-34 | Post authorisation safety study to prospectively monitor the incidence of relevant drug-related adverse events and EPO-related lack of efficacy among CKD subjects receiving HX575 recombinant human ery... | 2010-02-10 | due-trials |
| Reported results | 2008-002696-27 | An open label, single-arm, baseline-controlled, multicenter study to evaluate the efficacy, safety and immunogenicity of subcutaneous HX575 administered once a week (qw) and once every two weeks (q2w)... | 2009-08-04 | due-trials |
| Reported results | 2008-004340-37 | An open label, multinational, multicenter study to evaluate the safety of HX575 recombinant human erythropoietin alfa | 2012-07-02 | due-trials |
| Reported results | 2008-004351-29 | OPEN LABEL, MULTICENTER STUDY ON PHARMACOKINETICS, PHARMACODYNAMICS, EFFICACY AND SAFETY OF GOSERELIN 10.8 mg IMPLANT HEXAL IN PATIENTS WITH ADVANCED HORMONE DEPENDENT PROSTATE CANCER | 2009-06-29 | due-trials |
| Exempt, with results | 2009-017099-25 | A Pilot Pharmacodynamic/Pharmacokinetic Study of Fluticasone Propionate Administered as a Dry Powder in Patients with Asthma. | 2010-10-31 | not-yet-due |
| Exempt, with results | 2010-018712-32 | A Pilot Pharmacodynamic/Pharmacokinetic Study of SalmeterolXinofoate as a Dry Powder in Combination with Fluticasone in Patients with Asthma for Dose-Scale Bronchodilator Model Development. | 2010-09-30 | not-yet-due |
| Reported results | 2010-019522-13 | A randomized, controlled, double-blind Phase III trial to compare the efficacy, safety and pharmacokinetics of GP2013 plus Cyclophosphamide, Vincristine, Prednisone vs. MabThera® plus Cyclophosphamide... | 2018-01-22 | due-trials |
| Reported results | 2010-021184-32 | A randomized, double-blind, controlled study to evaluate pharmacokinetics, pharmacodynamics, safety and efficacy of GP2013 and rituximab in patients with rheumatoid arthritis refractory or intolerant... | 2016-11-10 | due-trials |
| Reported results | 2010-024481-22 | A randomized, double-blind, parallel-group, multi-center Phase III study comparing the efficacy and safety of EP2006 and Neupogen® in breast cancer patients treated with myelosuppressive chemotherapy | 2013-06-17 | due-trials |
| Reported results Terminated | 2011-001118-32 | Twelve-month study on the immunogenicity, safety, and efficacy of Zarzio®/Filgrastim HEXAL® in patients with severe chronic neutropenia | 2015-09-25 | due-trials |
| Reported results | 2011-002871-40 | Open label, single arm, multicenter study to evaluate the safety and immunogenicity of HX575 epoetin alfa in the treatment of anemia associated with chronic kidney disease in pre-dialysis and dialysis... | 2014-10-31 | due-trials |
| Reported results | 2011-004532-58 | A randomized, double-blind, parallel-group, multi-center Phase 3 comparative study investigating efficacy and safety of LA-EP2006 and Neulasta® in breast cancer patients treated with myelosuppressive ... | 2014-02-07 | due-trials |
| Reported results | 2012-002009-23 | A randomized, double-blind, parallel-group Phase III study to demonstrate equivalent efficacy and to compare safety and immunogenicity of GP2015 and Enbrel® (EU-authorized) in patients with moderate t... | 2017-06-12 | due-trials |
| Reported results | 2012-002011-26 | A randomized, double-blind, multicenter study to demonstrate equivalent efficacy and to compare safety and immunogenicity of a biosimilar etanercept (GP2015) and Enbrel® in patients with moderate to s... | 2015-03-30 | due-trials |
| Reported results | 2012-002039-28 | Pivotal study in breast cancer patients investigating efficacy and safety of LA-EP2006 and Neulasta® Estudio pivotal en pacientes con cáncer de mama para investigar la eficacia y seguridad de LA-EP... | 2013-12-04 | due-trials |
| Reported results | 2012-003876-38 | A randomized, double- blind, controlled, parallel-group, multicenter study to assess the safety and immunogenicity of transitioning to GP2013 or re-treatment with Rituxan® or MabThera® in patients wit... | 2016-10-12 | due-trials |
| Reported results | 2013-000747-11 | A randomized, double-blind, multicenter study to demonstrate equivalent efficacy and to compare safety and immunogenicity of a biosimilar adalimumab (GP2017) and Humira® in patients with moderate to s... | 2016-02-25 | due-trials |
| Exempt | 2014-001089-90 | Study to Test the Product Robustness of a Dry Powder Inhalation Device When Used in Normal Clinical Practice with Young Asthma Patients | not-yet-due | |
| Trial is outside EEC, and reported results | 2015-002802-34 | Multicentre study to evaluate the efficacy and safety of a liquid formulation of recombinant growth hormone, Omnitrope® 3.3mg/mL, in the treatment of pre-pubertal children of small stature suffering f... | bad-data | |
| Reported results | 2015-003433-10 | GP17-302 A randomized, double-blind, parallel-group, multicenter study to demonstrate similar efficacy and to compare safety and immunogenicity of GP2017 and Humira® in patients with moderate to sever... | 2017-09-26 | due-trials |
| Exempt, with results | 2018-003523-11 | A randomized, double-blind, multicenter integrated phase I/III study in postmenopausal women with osteoporosis to compare the pharmacokinetics, pharmacodynamics, efficacy, safety and immunogenicity of... | 2022-04-22 | not-yet-due |
| Reported results | 2019-000060-20 | Efficacy and safety of acetylcysteine for the treatment of acute uncomplicated rhinosinusitis: a prospective, randomized, double-blind, placebo-controlled trial Wirksamkeit und Sicherheit von Acety... | 2021-04-20 | due-trials |
| Reported results | 2019-004838-41 | A 52-week multicenter, randomized, double-masked, 2-arm parallel study to compare efficacy, safety and immunogenicity of SOK583A1 to Eylea®, administered intravitreally, in patients with neovascular a... | 2023-05-10 | due-trials |